Medical Therapeutics: From Conception to Puberty

Area of Science:

• Veterinary Pharmacology
• Pediatric Drug Safety

Background:

• Neonatal and pediatric veterinary patients exhibit significant physiological differences compared to adults.
• These differences profoundly impact drug pharmacokinetics (absorption, distribution, metabolism, excretion) and pharmacodynamics.

Purpose of the Study:

• To review age-specific considerations for pharmacologic treatments in neonatal and pediatric veterinary patients.
• To identify safe and contraindicated drug classes based on patient age.

Main Methods:

• Literature review focusing on drug pharmacokinetics and pharmacodynamics in young animals.
• Analysis of age restrictions and adverse effects for common veterinary medications.
• Examination of information sources like package inserts for pediatric drug data.

Main Results:

• Beta-lactam antimicrobials and opioids are generally considered safe for neonatal and pediatric use.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in animals under 6 weeks.
• Alpha-2 agonists and acepromazine are contraindicated in animals younger than 12 weeks.
• Fluoroquinolones and tetracyclines possess age-specific adverse effects.
• Premarket drug testing in animals under 6 months is infrequent, highlighting the importance of package inserts.

Conclusions:

• Pharmacologic management in young animals necessitates a thorough understanding of age-related physiological variations.
• Careful selection of medications, considering specific age contraindications and potential adverse effects, is crucial for pediatric veterinary patients.
• Utilizing available drug information, such as package inserts, is vital for ensuring safe and effective treatment in this population.